ReviewAnimal models and experimental medicine2026
Animal models of chronic thromboembolic pulmonary hypertension.
Review in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, yet life-threatening disorder characterized by persistent pulmonary vascular obstruction and elevated pulmonary artery pressure, with progressive remodeling and subsequent right heart failure. Despite substantial progress in elucidating the pathophysiology of CTEPH, the molecular mechanisms driving disease initiation and progression remain incompletely defined. Bridging these knowledge gaps and enabling the development of CTEPH-specific therapeutic strategies depend on experimental models that faithfully recapitulate the key pathological features observed in patients. A wide range of small- and large-animal models has therefore been established to mimic CTEPH development, each offering specific strengths and inherent limitations. Small animal models are relatively inexpensive, readily amenable to genetic manipulation, and well suited for high-throughput mechanistic investigations. However, their capacity to reproduce the complex pulmonary vascular architecture and hemodynamic characteristics of human disease is limited. By comparison, large-animal models more closely approximate human pulmonary anatomy and cardiovascular physiology, making them particularly valuable for detailed hemodynamic measurements and advanced imaging studies. Their broader application, however, is constrained by high financial costs, ethical considerations, and the need for specialized surgical and monitoring techniques. In this review, we provide an overview of currently available animal models of CTEPH, with emphasis on their methodological features, their ability to reproduce clinically relevant disease characteristics, and their potential utility in preclinical and translational research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.